Anaesthetic formulation
The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.
1. An anaesthetic or sedative composition consisting of:
(a) alphaxalone or a deuterated, tritiated or labelled derivative or salt thereof;
(b) (7) sulfobutyl ether β-cyclodextrin (SBECD) or an alkyl ether derivative thereof;
(c) an aqueous solvent suitable for injectable administration;
(d) optionally alphadolone or a deuterated, tritiated or labelled derivative or salt thereof, and
(e) optionally one or more additional components selected from the group consisting of a buffer, an excipient, a preservative, an anti-microbial agent, an agent that reduces toxicity and a co-polymer that improves solubility and/or stability;
wherein the molar complexation ratio of alphaxalone or a deuterated, tritiated or labelled derivative or salt thereof to SBECD or an alkyl ether derivative thereof is from 1:1.6 to 1:2.5.
2. The composition of claim 1 wherein the molar ratio of alphaxalone or a deuterated, tritiated or labelled derivative or salt thereof to SBECD or an alkyl ether derivative thereof is 1:2.
3. The anaesthetic or sedative composition of claim 1 , wherein the alkyl ether derivative of SBECD is sulfobutyl ether-alkyl ether cyclodextrin.
4. The anaesthetic or sedative composition of claim 1 wherein the alkyl ether derivative of SBECD is sulfobutyl ether-ethyl ether β-cyclodextrin or its sodium salt.
5. The anaesthetic or sedative composition of claim 1 , wherein the composition comprises alphadolone or a deuterated, tritiated or labelled derivative or salt thereof.
6. A method of inducing or maintaining anaesthesia or sedation in a subject comprising administering to said subject by infusion or intermittent bolus an anaesthetic or sedative composition according to claim 1 .
7. The method of claim 6 wherein alphaxalone is used at an anaesthetic concentration of 0.25 mg/kg to 100 mg/kg body weight.
8. The method of claim 6 wherein the alphaxalone is used at a sedating concentration of 0.05 mg/kg to 10 mg/kg body weight.
9. The method of claim 6 , wherein the subject is a human.